Scientists had the good fortune to study the exceedingly rare instance of a pair of identical twins, only one of whom had Trisomy 21. It turned out that gene regulation was altered across the entire genome in the twin with Down’s syndrome.
Deep-brain stimulation of the nucleus basalis of Meynert appeared safe and tolerable for Alzheimer’s patients.
Death receptor role in Alzheimer's disease looks less likely than was originally thought following a high-profile paper in 2009.
People with Alzheimer’s disease and other dementias may benefit from creative activities, but hard studies are still lacking.
Researchers have detected elevated endogenous tau in the cerebrospinal fluid of Aβ mouse models.
Satori Pharmaceuticals, which had been developing γ-secretase modulators for the treatment of Alzheimer's disease, has closed its doors...
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Hunting for rare mutations that cause dementia, researchers have spotted, but not yet snagged, some tantalizing candidates.
A parkinsonism-associated ubiquitin ligase interacts with parkin to promote mitophagy.
Rare variants of AD share some common areas of brain atrophy, but are also unique by way of degeneration in specific functional networks that correspond with clinical symptoms.
Brain connections weaken years before cognition in sporadic and familial Alzheimer’s.
Preliminary data from Parkinson’s Progression Markers Initiative suggests that cerebrospinal fluid biomarkers distinguish the most rapidly progressing form of Parkinson’s.
Before cognition falters, Alzheimer’s disease wreaks havoc on synapses, the brain’s subcellular communication hubs.
Brain imaging distinguishes ALS patients with C9ORF72 expansions from those with other forms of the disease.